Abstract

The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of product characteristics. In April 2019, a scientific meeting was held with the participation of nine experts from four Central and Eastern European countries to provide expert consensus on the optimal daily use of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning and initiation of iGlarLixi and the management of treatment. This paper summarizes the outcomes of the meeting.

Details

Title
Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
Author
Haluzík, Martin 1 ; Flekač, Milan 2 ; Lengyel, Csaba 3 ; Taybani, Zoltán 4 ; Guja, Cristian 5 ; Mihai, Bogdan-Mircea 6 ; Cerghizan, Anca 7 ; Martinka, Emil 8 ; Kovacs, Gabor 9   VIAFID ORCID Logo  ; Kempler, Péter 10 

1  Institute for Clinical and Experimental Medicine (IKEM), Diabetes Centre, Prague, Czech Republic (GRID:grid.418930.7) (ISNI:0000 0001 2299 1368) 
2  Charles University in Prague, Third Department of Internal Medicine, 1st Faculty of Medicine, Prague, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X) 
3  University of Szeged, First Department of Internal Medicine, Faculty of Medicine, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625) 
4  Békés County Central Hospital, Dr Réthy Pál Member Hospital, 1st. Department of Endocrinology, Békéscsaba, Hungary (GRID:grid.9008.1) 
5  Carol Davila University of Medicine and Pharmacy, Bucharest, Romania National Institute of Diabetes, Nutrition and Metabolic Diseases “NC Paulescu”, Bucharest, Romania (GRID:grid.8194.4) (ISNI:0000 0000 9828 7548) 
6  “Grigore T. Popa” University of Medicine and Pharmacy, Unit of Diabetes, Nutrition and Metabolic Diseases, Iaşi, Romania (GRID:grid.411038.f) (ISNI:0000 0001 0685 1605); “Sf. Spiridon” Emergency Hospital, Iaşi, Romania (GRID:grid.411038.f) 
7  Clinical Center of Diabetes, Nutrition, Metabolic Diseases, Cluj-Napoca, Romania (GRID:grid.411038.f) 
8  National Institute for Endocrinology and Diabetology, Lubochna, Slovak Republic (GRID:grid.411038.f) 
9  Syreon Research Institute, Budapest, Hungary (GRID:grid.411038.f) 
10  Semmelweis University, First Department of Medicine, Faculty of Medicine, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821) 
Pages
1029-1043
Publication year
2020
Publication date
Apr 2020
Publisher
Springer Nature B.V.
ISSN
18696953
e-ISSN
18696961
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1007/s13300-020-00777-2
ProQuest document ID
2512386117
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.